Tag: bd

BD announces enrolment in postmarket studies of the WavelinQ endoAVF system

BD announced today that enrolment has begun and the first patients have been treated in the postmarket surveillance study, CONNECT-AV. CONNECT-AV is a prospective, single-arm,...

Case report: Complex endovascular treatment for an iliac artery occlusion using...

This advertorial, sponsored by BD, is only available in selected countries and geographies. Martin Schroeder—a vascular surgery specialist at the Ruhr University Bochum Marienhospital...

FDA advisory panel recommends against premarket approval of Lutonix 014 DCB...

A US Food and Drug Administration (FDA) advisory panel has recommended against premarket approval of BD’s Lutonix 014 drug-coated balloon (DCB) for use in...
Lutonix

Six-month results of Lutonix AV Global registry published

Six-month results of the Lutonix arteriovenous (AV) Global registry were recently published in the Journal of Vascular and Interventional Radiology (JVIR). The data confirm...

CLEAN3 trial outlines potential new best practices for peripheral IV catheters

BD today announced that new clinical data have found robust evidence that using a vascular care solution can help improve outcomes for patients requiring...
Avenu Ellipsys

Ellipsys system offers greater patient eligibility and reduced time to dialysis,...

Two devices for creating minimally invasive dialysis access—the Ellipsys vascular access system (Avenu Medical) and the WavelinQ 4F system (BD)—demonstrated high rates of technical...
covered

24-month AVeNEW study results: Covered stent angioplasty “statistically superior” to angioplasty...

Against the backdrop of increasing end-stage renal disease (ESRD) prevalence in the USA, Bart Dolmatch (Portola Valley, USA) presented the 24-month results of the...

BD announces launch of Halo One thin-walled guiding sheath

BD has announced the launch of the Halo One thin-walled guiding sheath, designed to perform as both a guiding sheath and an introducer sheath,...
straub

Straub Medical acquired by BD

Straub Medical has approved a full acquisition by Becton, Dickinson and Company (BD). The acquisition was completed on 20 April 2020. Straub Medical manufactures,...
Venovo venous stent

A Deeper Dive into the Venovo™ Venous Stent System

The venous space continues to evolve in the United States, and many physicians are learning how to navigate through the challenges of the venous...

A Deeper Dive into the Venovo™ Venous Stent System

Vascular News talks with Gerard O'Sullivan, FSIR, FEBIR, University College Hospital, Galway, Ireland. This article is supported by BD Interventional. Disclosures: Dr. Gerard O'Sullivan reports...

LINC 2020: BD announces long-term safety data for BTK drug-coated balloon

Today at the 2020 Leipzig Interventional Course (LINC; 28–31 January, Leipzig, Germany), BD announced that interim findings from the Lutonix below-the-knee (BTK) investigational...
Lutonix

BD announces publication of drug-coated balloon safety data for femoropopliteal PAD

BD has announced the publication of a company-initiated, independent analysis of the Lutonix 035 drug-coated balloon (DCB) femoropopliteal clinical programme in the Journal of...

FDA notifies BD that Lutonix paclitaxel balloon PMA application for below...

The US Food and Drug Administration (FDA) have denied BD premarket approval (PMA) for the company’s Lutonix drug-coated balloon (DCB) in the treatment of...

FDA notifies BD that Lutonix paclitaxel balloon PMA request for below...

The US Food and Drug Administration (FDA) have denied BD premarket approval (PMA) for the company’s Lutonix drug-coated balloon (DCB) in the treatment of...
Lutonix

BD receives FDA approval for expansion to drug-coated balloon product line

The US Food and Drug Administration (FDA) has approved expanded sizes of the Lutonix 018 drug-coated balloon (DCB) to treat long superficial femoral artery...

BD announces launch of UltraScore 014 Focused Force PTA Balloon

BD has announced the launch of their UltraScore 014 Focused Force percutaneous transluminal angioplasty (PTA) Balloon. This marks the first scoring balloon with sheath...

BD receives FDA 510(k) clearance of WavelinQ 4F endoAVF system

BD has announced the 510(k) clearance from the US Food and Drug Administration (FDA) for the WavelinQ 4F endoAVF system earlier this month. The endoAVF...

Lutonix BTK randomised trial meets safety and efficacy endpoints at six...

Six-month outcomes of a multicentre randomised controlled trial using the Lutonix 014 drug-coated balloon (BD; DCB) has demonstrated the DCB is safe to use...

BD acquires TVA Medical, makers of everlinQ endoAVF System

BD (Becton, Dickinson and Company) announced it has completed the acquisition of TVA Medical, a company that develops minimally invasive vascular access solutions...

BD announces completion of enrolment in Lutonix 014 DCB below-the-knee trial

Enrolment is complete in the Lutonix below-the-knee trial with BD planning to submit a pre-market approval application to the US Food and Drug Administration...

BD completes acquisition of Bard

BD, a leading global medical technology company, has announced it has completed the acquisition of C R Bard, creating a new health care industry...

European Commission approves BD acquisition of Bard, subject to conditions

The European Commission has approved, under the EU Merger Regulation, the acquisition of Bard by BD. The decision is conditional on the divestment of...

BD to acquire Bard for US$24 billion

BD (Becton, Dickinson and company) has definitively agreed to acquire Bard for US$317 per common share in cash and stock, for a total consideration...